Smoking cessation · young people
It is very uncertain whether pharmacological interventions changes bupropion vs placebo Smoking cessation compared with placebo (very low certainty).
3 findings from 1 review
RR 1.49 [0.55, 4.02]
1 study · 207 participants
Very low
RR 1.05 [0.41, 2.69]
1 study · 211 participants
Very low
RR 1.11 [0.48, 2.58]
2 studies · 385 participants
Very low
Adverse events (control ‐ placebo) · young people
3 findings from 1 review
no estimate extracted
1 study · 207 participants
Very low
no estimate extracted
1 study · 211 participants
Very low
no estimate extracted
2 studies · 385 participants
Very low
Depression: meeting study criteria for depression at end of · people with depression after stroke
It is very uncertain whether pharmacological interventions changes depression: meeting study criteria for depression at end of… compared with placebo (very low certainty).
2 findings from 1 review
Depression: < 50% reduction in scale scores at end of treatment (primary outcome) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes depression: < 50% reduction in scale scores at end of treatment… compared with placebo (very low certainty).
1 finding from 1 review
Depression: mean scores at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: death (secondary outcome) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects (central nervous system) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ central nervous system events (e.g. confusion,… compared with placebo (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ gastrointestinal effects (e.g. constipation,… compared with placebo (very low certainty).
1 finding from 1 review
Incidence of depression ‐ short‐term: < 6 months · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes incidence of depression ‐ short‐term: < 6 months compared with placebo (very low certainty).
1 finding from 1 review
Incidence of depression ‐ medium term: 6‐12 months · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes incidence of depression ‐ medium‐term: 6‐12 months compared with placebo (very low certainty).
1 finding from 1 review
Incidence of depression ‐ long‐term: >12 months · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Tolerability ‐ total number of adverse events · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
acceptability ‐ drop‐outs due to adverse events: post‐intervention · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes acceptability ‐ drop‐outs due to adverse events: post‐intervention compared with placebo (very low certainty).
1 finding from 1 review
Acceptability · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes acceptability ‐ drop‐outs due to any cause: post‐intervention compared with placebo (very low certainty).
2 findings from 1 review
Incidence of depression ‐ post‐intervention: 0 months · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes incidence of depression ‐ post‐intervention: 0 months compared with placebo (very low certainty).
1 finding from 1 review
Effect on later sexual function · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
1 finding from 1 review
Sexual satisfaction · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: quality of life · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Psychological well‐being (secondary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction with intervention (secondary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found